Amgen Inc. $AMGN Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC decreased its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 214,286 shares of the medical research company’s stock after selling 24,052 shares during the quarter. Amgen accounts for about 0.6% of Guggenheim Capital LLC’s holdings, making the stock its 19th largest holding. Guggenheim Capital LLC’s holdings in Amgen were worth $66,761,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. First Pacific Financial raised its holdings in Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company’s stock worth $28,000 after purchasing an additional 67 shares during the period. Pinney & Scofield Inc. acquired a new position in Amgen in the 4th quarter worth about $26,000. Global Wealth Strategies & Associates raised its holdings in Amgen by 1,388.9% in the 1st quarter. Global Wealth Strategies & Associates now owns 134 shares of the medical research company’s stock worth $42,000 after purchasing an additional 125 shares during the period. Heck Capital Advisors LLC acquired a new position in Amgen in the 4th quarter worth about $36,000. Finally, South Plains Financial Inc. acquired a new position in Amgen in the 4th quarter worth about $37,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 0.4%

Shares of Amgen stock opened at $289.58 on Wednesday. The firm has a market capitalization of $155.90 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 2.48 and a beta of 0.49. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $339.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The stock has a 50 day moving average of $293.28 and a 200 day moving average of $293.08.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping the consensus estimate of $5.28 by $0.74. The company had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the prior year, the business posted $4.97 earnings per share. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 12th. Investors of record on Friday, August 22nd will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.3%. The ex-dividend date is Friday, August 22nd. Amgen’s dividend payout ratio is presently 77.84%.

Insider Activity at Amgen

In related news, SVP Nancy A. Grygiel sold 1,267 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares of the company’s stock, valued at $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of several research reports. Royal Bank Of Canada cut their price objective on Amgen from $324.00 to $320.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Morgan Stanley upped their price target on Amgen from $330.00 to $333.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Mizuho upped their price target on Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research report on Wednesday, May 7th. Citigroup upped their price target on Amgen from $305.00 to $310.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Finally, Guggenheim began coverage on Amgen in a research report on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $304.43.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.